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Genetically-modified T cells expressing chimeric antigen receptors (CAR) exert anti-tumor effect by
identifying tumor-associated antigen (TAA), independent of major histocompatibility complex. For
maximal efficacy and safety of adoptively transferred cells, imaging their biodistribution is critical. This will
determine if cells home to the tumor and assist inmoderating cell dose. Here, T cells aremodified to express
CAR. An efficient, non-toxic process with potential for cGMP compliance is developed for loading high cell
number with multi-modal (PET-MRI) contrast agents (Super Paramagnetic Iron Oxide Nanoparticles –
Copper-64; SPION-64Cu). This can now be potentially used for 64Cu-based whole-body PET to detect T cell
accumulation region with high-sensitivity, followed by SPION-based MRI of these regions for
high-resolution anatomically correlated images of T cells. CD19-specific-CAR1SPIONpos T cells effectively
target in vitro CD191 lymphoma.
P
re-clinical studies with light-emitting transgenes (e.g. Firefly Luciferase (ffLuc)) for bioluminescence (BL)
imaging cannot be used in large animal studies or human trials due to light attenuation in thicker tissues.
Thymidine kinase (TK) and associatedmuteins from herpes simplex virus-1 has been used to enzymatically
trap 18F-based probes in the cytoplasm for Positron Emission Tomography (PET)1 but non-metabolized 18F
contributes to background2. Short radioactive half-life of 18F (t1/2 5 109.8 min) and immunogenicity fromTK are
also of concern. Current clinical methods are therefore limited to quantitative PCR and flow cytometry with
CAR-specific probes from serially sampled tissues and peripheral blood2. Lack of non-invasive methods to track
cells with whole-body and real-time capability is therefore an unmet clinical need3.
Super Paramagnetic Iron-Oxide Nanoparticles (SPION) have been successfully used as Magnetic Resonance
Imaging (MRI) contrast agents for high resolution imaging of cells without substantial impact on cell viability4,5.
WhileMRI of SPION-labeled cells has been used for investigating pre-identified site, e.g. engrafted tumor, it lacks
the sensitivity for systemically infused cells and whole-body assessment. 64Cu-based PET has been used to track
cells up to 48 hrs6. Our recent work on in vivo cell imaging also demonstrates the use of 64Cu PET tracer
conjugated to gold nanoparticle (GNP-64Cu) for labeling primary T cells7.
Therefore, we conjugated SPION with a positron emitter, copper-64 (64Cu) (t1/2 5 12.7 hr), through macro-
cyclic chelator (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTA) (SPION-64Cu); before labeling
the cells with this dual-modality complex8. PET has the sensitivity and capability for whole-body assessment and
can therefore provide approximate location of cells that can be further investigated by SPION-based MRI to
obtain anatomically correlated high-resolution imaging. This strategy is in compliance with newly emerging
PET-MRI scanners.
In this study, as per the schematic shown in Figure 1, we have adapted charges on the SPION-64Cu
complex9 and dimethyl sulfoxide (DMSO) to translocate the multi-modal nanoparticle complex into the
non-phagocytic primary T cells10 within 10 minutes at 100% efficiency without causing any toxicity to the
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cells. A fluorescent modality conjugated to this contrast agent fur-
ther enabled validation studies. Finally, in an in vitro B-cell lym-
phoma tumor model, we demonstrated that SPION-labeled T cells
retain tumor-killing function. Our work has translational implica-
tions as the cell manufacturing, imaging and contrast agents can
potentially be made available in compliance with cGMP for Phase
I/II clinical trials.
Results and Discussion
Electroporation offers the advantage of instant cargo transport into the
cytoplasm. However, it is a harsh process and subjects the cells and
GNP-64Cu to a pulse of up to 200 V7. We have previously electro-
transferred GNP-64Cu into the T cells for PET tracking. However, only
up to 50% cells survived and the remaining cells perished in vivowithin
4 to 12 hr. (Supplementary Fig. S1). Further, limited electroporation
Figure 1 | CAR1EGFPffLucHyTK1SPIONpos T cells. (a) Schematic for the generation of cells. (b) Positively charged SPION or SPION-FL or
SPION-64Cu.
Figure 2 | Loading of T cell with SPION. (a) Flow cytometry shows transport of SPION into T cells is proportional to DMSO concentration. (b) Flow
cytometry shows loading of SPION into T cells is complete within 10 min. (n 5 3) (c) Firefly luciferase (ffLuc) activity shows cell viability is reduced
beyond 10 min labeling time. ffLuc activity is also reduced as a result of loading the T cells with SPION. (n5 3) (d) Flow cytometry shows the retention of
SPION in CAR1EGFPffLucHyTK1SPIONpos T cells and Trypan blue dye exclusion method shows the impact of SPION on T cell viability and
proliferation. (e) Confocal microscopy shows that SPION are internalized in the T cells. Error bars indicate standard deviation.
www.nature.com/scientificreports
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reaction volume (100 mL) poses a pragmatic challenge for clinical
translation. (All mice were handled in accordance with guidelines from
Animal Care and Use Committee at The Methodist Hospital Research
Institute).
The challenge therefore was to develop a process that could label
high-numeric count of T cells within minutes with SPION-64Cu,
without causing toxicity to the T cells. This fast labeling process
would reduce the incidence of radiation-induced cell death because
it will reduce the – (1) exposure time to 64Cu during the labeling
process; and (2) quantity of 64Cu required for labeling due tominimal
radioactive decay. Therefore, we investigated the interaction of nano-
particle surface charges with loading buffer formulation to enable
transient pores in the cell membrane without the use of electric
shock. We argued that a positive charge on the SPION will allow
for their proximity to the negatively charged cell membranes9 that
may be transiently permeablized in a controlled manner in presence
of DMSO for crossing the membrane barriers by SPION derivatives.
Our initial experiments showed direct dependence of the SPION
internalization on DMSO concentration and loading time
(Figure 2a). BL activity from ffLuc enzyme was used to indicate cell
viability as ffLuc enzyme, co-expressed in these cells, requires ATP as
a co-factor which is present only in live cells.
Therefore, for all future experiments labeling/loading parameters
were fixed at: primary T cells – 100 3 106; SPION derivative with
positive zeta potential (120 to 130 mV) (SPION, SPION-FL or
SPION-64Cu) – 100 mL, 2 mg/mL in 0.01 M PBS with 3% DMSO
(Sigma, Cat # D2650); incubation time – 10 min; temperature
237uC.
Figure 2b shows the loading kinetics and degree of loading as a
function of time. Flow cytometry showed almost complete cell popu-
lation was loaded within 10 min. This was further confirmed by iron
content analysis (Supplementary Fig. S2). The decline in ffLuc activ-
ity (Figure 2c) indicated that extending the labeling time beyond
10 min offered no added benefit. Figure 2c also show substantial
reduction in ffLuc activity when primary T cells were loaded with
nanoparticles. Although the decline of ffLuc activity in same cell
population over a certain time period may be interpreted as the
decline in cell viability, this may not be the case for SPIONpos T cells
compared with SPIONneg T cell controls at the same time point. This
decline in ffLuc activity at the same time point might be the result of
SPION interfering either with ffLuc activity or with molecular cas-
cade inhibiting the BL emission that may not lead to an apoptotic
event. This is further supported by the results of Figure 2d where
continuous cell expansion is observed over a period of 5 days.
The experiment for Figure 2d was designed to answer an import-
ant question in context of using this technology for T cell tracking, i.e.
how long the SPION last inside the cells. SPIONpos T cells were
cultured in 24-well plates. Each well (3 mL) was harvested at fixed
time point and the cell membranes were cross-linked using 4% para-
formaldehyde fixation buffer (BD Cytofix). 1 ml of IL-2 was added to
each remaining well every 24 hr period and evaluated for cell count,
cell viability, median fluorescence intensity (MFI), and the percent-
age of labeled population of cells. Our results indicate healthy state of
cells when estimated through Trypan blue dye exclusion viability
test, along with constant increase in cell count. A sudden decline
in labeled population occurs around 30 hr which is expected as a
result of considerable increase in cell count. As discussed before in
context of cell viability (Figure 2c), this is a strong indication that
decline in ffLuc activity in SPIONpos T cells does not indicate the loss
of cell viability. Continuous decline in MFI (Figure 2d) is expected
due to cell division and propagation.
Development of methods for loading primary cells is important
for advancing gene therapies. In our DMSO-based technique, an
important question needs to be answered – do the nanoparticles
translocate across the cellular membrane or simply adhere to the cell
surface9. Confocal microscopy (Figure 2e) provide necessary and
sufficient evidence that although SPION are seen adhering to the cell
membrane, we also see them circumscribed by cell membrane,
indicating that the SPION-FL indeed make it across the cellular
membrane. This is of further importance as pseudoautocrine stimu-
lation from nanoparticles conjugated to the T cells surface has been
Figure 3 | Effect of SPION-64Cu on T cell viability and imaging. (a)
Reduction in ffluc activity as a result of SPION and SPION-64Cu shows
interference with the enzymatic activity. (n 5 3) (b) WST-1 assay shows
that T cell viability before and after loadingwith SPIONand SPION-64Cu is
comparable. (n5 3) (c)MRI contrast fromdilution series of SPIONneg and
SPIONpos T cell phantoms obtained with spin echo and gradient echo
sequences. Error bars indicate standard deviation.
www.nature.com/scientificreports
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shown to improve their in vivo propagation and improve tumor
elimination13.
Once the loading and release kinetics of SPION in primary T cells
were established, we focused our efforts towards imaging of T cells.
As the cell therapies and transplant technologies mature towards
clinic, substantial efforts are beingmade towards developing imaging
technologies for tracking therapeutic cells. MRI, photo-acoustic
imaging and Raman imaging has been used for triple-modal imaging
agents for surgical resection of brain tumor in mice14. SPECT/MRI
dual imaging has been demonstrated before by labeling immature
dendritic cells, which are phagocytic in nature, separately with In-
111 and SPION and co-injecting equal numbers of differently labeled
cells15. Magnetodendrimers have been used to label primary neural
stems cells and mesenchymal stem cells for MRI tracking5. Recent
use of MRI contrast agent includes an in vivo sensor indicating
necrotic or apoptotic cells16.
For PET imaging of cells, we replaced SPION (2 mg/mL) with
concoction of SPION and SPION-64Cu. Our initial experiments indi-
cated complete loss of cell viability as indicated by ffLuc activity, the
cause of which was determined to be radiation damage from 64Cu
Figure 4 | Targeting capability of CD19-specific-CAR1EGFPffLucHyTK1SPIONpos T cells (SPIONpos effector T cells) towards CD191NALM-6 B-cell
lymphoma in vitro model (target cells). (a) Chromium release assay shows comparison of tumor lysing capability of SPIONpos effector T cells and
SPIONneg effector T cells. (n5 3) Error bars indicate standard deviation. (b) Snapshots in time (Frame i–v) from live-cell time-lapse imaging of target cell
undergoing apoptotic cell death after being engaged by the SPIONpos effector T cells. Scale Bar: 5 mm.
www.nature.com/scientificreports
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(Supplementary Fig. S3).We then improvised our protocols for min-
imal 64Cu to limit the radioactivity at 0.6 mCi (SPION – 2 mg/mL,
64Cu – 0.6 mCi), which the cells could be exposed to without losing
substantial ffLuc activity and viability as indicated by BL emission
and WST-1 Cell Proliferation Assay (Roche Applied Science,
Indianapolis, IN), respectively. Cellular uptake of 50.8 6 0.4%
(n 5 3) (i.e. approximately 0.3 mCi) was observed using gamma
scintillation counter and up to 2.4 pg Fe/T cell uptake was observed.
Together with our previously published results in in vivo PET
imaging of 64Cu labelled cells7, we believe that PETwill be an efficient
imaging modality for in vivo imaging of these cells. The sensitivity of
such imaging protocol will also depend on loading the cells with 64Cu
and the number of infused cells.
The ffLuc activity (Figure 3a) and WST-1 assay (Figure 3b) was
conducted each day over a period of 5 days as per manufacturer’s
protocol. The results show decrease in ffLuc activity from SPIONpos T
cells which further decreased in SPION-64Cupos T cells but stayed
approximately constant in both cell populations after day 1. IL-2
was not added to these cell cultures during these 5 days to deconvo-
lute any proliferation effect that may mask any unexpected toxicity
fromSPIONand 64Cu. In order to account for any loss of viability due
to non-addition of IL-2, (see Supplementary Fig. S4 for intrinsic loss
of T cell viability) the data points from SPIONpos T cells and
SPION-64Cupos T cells were normalized with respect to the corres-
ponding data point from the control SPIONneg T cells.
Figure 3c shows theMRI contrast from dilution series of SPIONpos
T cell phantoms with spin echo and gradient echo sequences. Top
row contains SPIONpos T cell phantoms and bottom row contains the
negative control with same number of SPIONneg T cells. Upon visual
inspection, we are able to obtain contrast from approximately 5000
cells per voxel using either of the two sequences. Although, our
research was mainly concentrated on transfer of SPION in genetic-
ally modified T cells while retaining their tumor specificity, we refer
the readers to the work of other research groups that have been able
to push the detection limit to a single lymphocyte per voxel17,18.
Our final and critical test was to assess the effect of SPIONonT cell
functionality. Primary human T cells genetically engineered to ex-
press CD19-specific CAR (effector cells) were loaded with SPION
(CAR1EGFPffLucHyTK1SPIONpos T cells, SPIONpos effector T cells)
and tested for their efficacy in targeting CD191 NALM-6 in vitro B-
cell lymphoma model (target cells) in chromium release assay
(Figure 4a). We observed, as shown in Figure 4a, that SPIONpos
effector T cells retain their tumor targeting capability. Although
when compared to SPIONneg effector T cells we observed a decrease,
this can simply be overcome by increasing the number of SPIONpos
effector T cells. E.g. percentage tumor cell lysis obtained by unlabeled
T cells at 551 (Effector5Target) is the same for labeled T cells at 1351.
Similar effect of non-biogenic substances can also be expected on the
immunological functioning of cells, e.g. production of IFNc, IL-2,
TNFa and should be assessed depending on the intended use of the
labelled cells. Figure 4b show snapshots in time from live-cell time-
lapse imaging of tumor lysing action (Supplementary Video 1 live-
cell time-lapse imaging) of the SPIONpos effector T cells. B-cell
lymphoma cell, which is initially mobile, is engaged by the effector
SPIONpos T cell at 1 hr 40 min. At 2 hr 40 min the effector cell
disengages and lysis of the target cell is evident.
The growing importance of adoptive T cell therapies is summar-
ized in the following excerpt from the recent editorial19, ‘‘ACT
(Adoptive Cell Therapy) is unlike any other cancer treatment. It
can seek out cancer in places other therapies cannot. It can lead to
memory T cells that persist in patients far longer than any other
therapy, continuously eliminating residual cancer cells. And most
importantly, it can induce dramatic complete remissions in patients
for whom no other options exist.’’
In this work, towards our long-term goal of integrating and enhan-
cing immunotherapies with physical technologies, we have enabled
technology for loading of multi-modal imaging agents into non-
phagocytic primary T cells10. We studied the interaction of T cells
with nanoparticles and the interaction of nanoparticle-modified T
cells with their tumor targets and this approach is extendible to other
cell therapies. With diminishing barriers among materials science,
nanotechnology and immunotherapies, substantial opportunities
exist for enhancing human health20. Choosing the correct imaging
modes and developing an imaging strategy that fits within the lim-
itation of the clinical trial is critical for safety4. As the next phase of
this project, our efforts are focused on expanding this program by
monitoring the T cells as they home to their tumor targets and to
determine the optimal T-cell drug load in vivo to maintain cytotoxic
pressure on the tumor cells.
Methods
Generation of CAR1EGFPffLucHyTK1T cells. TAA-specific-CAR1 T cells are able
to target tumor cells independent of major histocompatibility complex. To
manufacture T cells (see Figure 1) with CD19-specific-CAR expression we have
adopted Sleeping Beauty (SB) transposon/transposase system7 to genetically modify
primary peripheral blood mononuclear cells (PBMC). Second-generation CD19-
specific-CAR (that signals through CD28 and CD3-f)11 were expressed on T cell
surface and the cells were selectively propagated on a master cell-bank of artificial
antigen presenting cells (aAPC)12. (See Supplementary Information for detailed
protocol). These have application in clinical trials for patients with CD191 B-cell
malignancies. The gene expression panel was expanded to include the expression of
ffLuc in T cells as a BL reporter gene12.
Loading of T cells with SPION derivatives. Primary T cells – 100 3 106 were
incubated at 37uC with SPION derivative (SPION, SPION-FL or SPION-64Cu from
BioPhysics Assay Laboratory, Inc, Worcester, MA) – 100 mL, 2 mg/mL in 0.01 M
PBS with 3% DMSO (Sigma, Cat # D2650). Cells were washed twice with 30 mL
0.01 M PBS (Sigma, Cat # D8537) and centrifuged at 200 g, 8 min. (See
Supplementary Information for detailed protocol).
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